PCSK9 inhibition: the way forward in the treatment of dyslipidemia

Abstract

Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progress from PCSK9 discovery to the development of targeted… (More)
DOI: 10.1186/s12916-015-0503-4

Topics

2 Figures and Tables

Slides referencing similar topics